Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study: Enhancing Donor Hematopoietic Cell Engraftment With Plerixafor in Myeloablative Allogeneic Hematopoietic Cell Transplantation

NCT01280955 is registered in ClinicalTrials.gov with Mitchell Horwitz, MD as lead sponsor.

NCT NCT01280955
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01280955 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study: Enhancing Donor Hematopoietic Cell Engraftment With Plerixafor in Myeloablative Allogeneic Hematopoietic Cell Transplantation
Lead sponsor
Mitchell Horwitz, MD
Phase
Phase 1/2
Overall status
Completed
Start date
December 31, 2011
Completion date
May 31, 2015
Enrollment
41 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

failure of bone marrow graft